[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of relapsing-remitting MS, acute severe symptoms (bilateral leg weakness, urinary retention), new gadolinium-enhancing T2 lesion at T10, progression despite high-dose IV methylprednisolone, and CSF findings confirming MS (elevated IgG index, oligoclonal bands). These indicate a severe steroid-refractory relapse, making plasma exchange (A) the evidence-based next step per guidelines like AAN for rapid removal of inflammatory mediators. Main logical issue(s): none; the stem provides sufficient details to discriminate A as uniquely best without contradictions or underspecification. Alternatives are inferior: B (rituximab) and E (natalizumab) are long-term disease-modifying therapies, not for acute management; C (fingolimod) is a DMT potentially risky in active inflammation; D (repeat LP) is redundant with established diagnosis. Main medical accuracy issue(s): none; aligns with current standards for MS relapse management, where PLEX is indicated for severe, unresponsive attacks, and options reflect realistic clinical choices without inaccuracies or outdated info. Minimal fix: none needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of relapsing-remitting MS, acute severe symptoms (bilateral leg weakness, urinary retention), new gadolinium-enhancing T2 lesion at T10, progression despite high-dose IV methylprednisolone, and CSF findings confirming MS (elevated IgG index, oligoclonal bands). These indicate a severe steroid-refractory relapse, making plasma exchange (A) the evidence-based next step per guidelines like AAN for rapid removal of inflammatory mediators. Main logical issue(s): none; the stem provides sufficient details to discriminate A as uniquely best without contradictions or underspecification. Alternatives are inferior: B (rituximab) and E (natalizumab) are long-term disease-modifying therapies, not for acute management; C (fingolimod) is a DMT potentially risky in active inflammation; D (repeat LP) is redundant with established diagnosis. Main medical accuracy issue(s): none; aligns with current standards for MS relapse management, where PLEX is indicated for severe, unresponsive attacks, and options reflect realistic clinical choices without inaccuracies or outdated info. Minimal fix: none needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Incomplete C5 tetraplegia causing neurogenic orthostatic hypotension (OH), evidenced by significant BP drop on tilt (120/80 to 85/50 mmHg), minimal HR increase, and absent sympathetic skin response below lesion, indicating sympathetic autonomic disruption. The question seeks the most effective pharmacologic intervention for upright tolerance in this SCI context.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (neurogenic OH mechanism, lesion level) to identify midodrine as uniquely best, with alternatives inferior due to mechanisms or risks. Options are comparable pharmacologic choices, allowing clear discrimination without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; midodrine as an alpha-1 agonist for vasoconstriction in neurogenic OH aligns with current guidelines (e.g., Consensus Statement on Neurogenic OH), minimizing supine hypertension risk. Fludrocortisone risks edema/fluid overload; propranolol and clonidine may exacerbate hypotension via beta-blockade or central sympatholysis; ephedrine is less selective with more cardiovascular side effects. Item reflects standard care without inaccuracies or outdated elements.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Incomplete C5 tetraplegia causing neurogenic orthostatic hypotension (OH), evidenced by significant BP drop on tilt (120/80 to 85/50 mmHg), minimal HR increase, and absent sympathetic skin response below lesion, indicating sympathetic autonomic disruption. The question seeks the most effective pharmacologic intervention for upright tolerance in this SCI context.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (neurogenic OH mechanism, lesion level) to identify midodrine as uniquely best, with alternatives inferior due to mechanisms or risks. Options are comparable pharmacologic choices, allowing clear discrimination without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; midodrine as an alpha-1 agonist for vasoconstriction in neurogenic OH aligns with current guidelines (e.g., Consensus Statement on Neurogenic OH), minimizing supine hypertension risk. Fludrocortisone risks edema/fluid overload; propranolol and clonidine may exacerbate hypotension via beta-blockade or central sympatholysis; ephedrine is less selective with more cardiovascular side effects. Item reflects standard care without inaccuracies or outdated elements.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include NF2 mutation confirmation, bilateral vestibular schwannomas causing vertigo, tinnitus, fluctuating hearing loss, and facial weakness, plus spinal ependymoma and gait instability, pointing to progressive NF2-related tumors requiring targeted stabilization. The question asks for the most appropriate targeted therapy for tumor stabilization in this NF2 patient. Discriminating findings: genetic confirmation and tumor types typical of NF2, with progressive symptoms implying need for non-surgical intervention. Most likely management: anti-angiogenic therapy to reduce vascularity. Keyed answer A (Bevacizumab) fits as it inhibits VEGF, stabilizing schwannomas per clinical trials with hearing benefits; assumes standard off-label use. Alternatives: B (Everolimus) targets mTOR but lacks NF2 specificity and strong evidence; C (Crizotinib) is ALK inhibitor irrelevant to NF2; D (Trametinib) MEK inhibitor for other pathways; E (Sorafenib) multi-kinase not indicated. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current evidence for Bevacizumab in progressive NF2 schwannomas (e.g., RETRO trial data), though it's off-label and not first-line for all cases, but appropriate here. Minimal fix: None required, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include NF2 mutation confirmation, bilateral vestibular schwannomas causing vertigo, tinnitus, fluctuating hearing loss, and facial weakness, plus spinal ependymoma and gait instability, pointing to progressive NF2-related tumors requiring targeted stabilization. The question asks for the most appropriate targeted therapy for tumor stabilization in this NF2 patient. Discriminating findings: genetic confirmation and tumor types typical of NF2, with progressive symptoms implying need for non-surgical intervention. Most likely management: anti-angiogenic therapy to reduce vascularity. Keyed answer A (Bevacizumab) fits as it inhibits VEGF, stabilizing schwannomas per clinical trials with hearing benefits; assumes standard off-label use. Alternatives: B (Everolimus) targets mTOR but lacks NF2 specificity and strong evidence; C (Crizotinib) is ALK inhibitor irrelevant to NF2; D (Trametinib) MEK inhibitor for other pathways; E (Sorafenib) multi-kinase not indicated. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current evidence for Bevacizumab in progressive NF2 schwannomas (e.g., RETRO trial data), though it's off-label and not first-line for all cases, but appropriate here. Minimal fix: None required, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (secondary: U). Verdict on keyed answer: Miskeyed. Key stem clues: 55-year-old with diabetic amyotrophy, severe proximal leg weakness/pain, L2-L4 denervation on EMG, persistent atrophy despite optimized glycemic control; seeking most evidence-based adjunctive therapy for functional recovery beyond PT. The clinical problem asks for the best adjunctive treatment to improve strength/recovery in refractory diabetic amyotrophy. Discriminating findings: confirmed diagnosis, glycemic control achieved, ongoing weakness/atrophy implying need for additional intervention. Most likely approach: supportive care, but evidence for immunomodulation is limited. Keyed answer A (IVIG) assumes autoimmune mechanism with benefit from case series, but lacks high-level evidence like RCTs; fits refractory cases but not definitively 'most evidence-based.' Alternatives: B (pyridostigmine) incorrect for neuropathy (neuromuscular junction disorder); C (gabapentin) addresses pain, not weakness/recovery; D (corticosteroids) sometimes used but risks hyperglycemia in diabetes; E (plasmapheresis) no supporting evidence. Main logical issue: Underspecified on evidence levels, leading to miskeyed; stem doesn't specify severity or prior trials to uniquely favor IVIG over corticosteroids, allowing multiple defensible options (A and D). Main medical accuracy issues: Overstates IVIG as 'evidence-based' – current standards (e.g., UpToDate, neurology guidelines) emphasize conservative management; immunotherapy experimental with weak evidence, no RCTs supporting IVIG superiority. Minimal fix: Change key to D or add stem detail 'contraindicated due to poor glycemic control risk' to eliminate D and make A unique.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (secondary: U). Verdict on keyed answer: Miskeyed. Key stem clues: 55-year-old with diabetic amyotrophy, severe proximal leg weakness/pain, L2-L4 denervation on EMG, persistent atrophy despite optimized glycemic control; seeking most evidence-based adjunctive therapy for functional recovery beyond PT. The clinical problem asks for the best adjunctive treatment to improve strength/recovery in refractory diabetic amyotrophy. Discriminating findings: confirmed diagnosis, glycemic control achieved, ongoing weakness/atrophy implying need for additional intervention. Most likely approach: supportive care, but evidence for immunomodulation is limited. Keyed answer A (IVIG) assumes autoimmune mechanism with benefit from case series, but lacks high-level evidence like RCTs; fits refractory cases but not definitively 'most evidence-based.' Alternatives: B (pyridostigmine) incorrect for neuropathy (neuromuscular junction disorder); C (gabapentin) addresses pain, not weakness/recovery; D (corticosteroids) sometimes used but risks hyperglycemia in diabetes; E (plasmapheresis) no supporting evidence. Main logical issue: Underspecified on evidence levels, leading to miskeyed; stem doesn't specify severity or prior trials to uniquely favor IVIG over corticosteroids, allowing multiple defensible options (A and D). Main medical accuracy issues: Overstates IVIG as 'evidence-based' – current standards (e.g., UpToDate, neurology guidelines) emphasize conservative management; immunotherapy experimental with weak evidence, no RCTs supporting IVIG superiority. Minimal fix: Change key to D or add stem detail 'contraindicated due to poor glycemic control risk' to eliminate D and make A unique.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]